Baker & Eastlack Ventures

MatriSys sees commercialization paths for its intellectual property in topical dermatology therapeutics, cosmetics, and skin care. The company’s lead live biologic therapeutic is currently in Phase I/II clinical trials targeting atopic dermatitis (commonly referred to as AD or eczema) patients.

Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions. Clarify Medical indicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction.

Lentechs is a medical device company that develops a novel soft bifocal contact lens. The company is headquartered in Columbus, Ohio.

Neurvana Medical is dedicated to the development of neurovascular therapeutic devices.

UroDev Medical designs devices to improve the quality of life for people with Spinal Cord Injury and Disease. Their first product, The Connected Catheter, will revolutionize the way millions of people deal manage their bladders.

Kurin® is a privately held, certified minority owned business dedicated to engineering better healthcare through innovative, cost-effective, clinician-approved technologies. Building on the successful invention, clinical adoption and corporate acquisition of Curos™ disinfecting port protectors, Kurin is focusing its depth of experience in medical device engineering, marketing, sales and service, to tackle the persistent and costly fallout of false positive blood cultures. With agile development capabilities and intense customer focus, we expect the Kurin Lock technology to quickly gain caregiver acceptance, reduce blood culture contamination and become the standard of care in hospitals.